SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Commission File Number)
(Address of principal executive offices)
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻
Item 5.07Submission of Matters to a Vote of Security Holders
Protalix Biotherapeutics, Inc. (the “Company”) reconvened its 2023 Annual Meeting of Stockholders (the “Meeting”). The Meeting was initially convened on June 28, 2023. At the reconvened Meeting, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of shares of its common stock, par value $0.001 per share, authorized for issuance from 144,000,000 to 185,000,000.
Set forth below, with respect to the proposal adopted at the Meeting, are the number of votes cast for or against and the number of abstentions.
Approval of an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of shares of its common stock, par value $0.001 per share, authorized for issuance from 144,000,000 to 185,000,000 to
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 13, 2023
PROTALIX BIOTHERAPEUTICS, INC.
/s/ Eyal Rubin
Sr. Vice President and